Project Finance Account Manager

Medpace Q3 earnings call highlights. October 22, 2026 Key points. * Medpace delivered strong third-quarter results: Revenue rose 8.5% to $716 million, net income increased 23.7% to $137.5 million, and diluted EPS grew to $4.84. EBITDA margin expanded to 24% from 22.5% a year earlier. * Management raised its 2026 outlook to $2.835 billion-$2.855 billion in revenue, $638 million-$652 million in EBITDA and diluted EPS of $17.97-$18.32. * Record awards strengthened future visibility: Third-quarter net new business awards reached $873.4 million, backlog grew 5.6% to approximately $3.2 billion, and the board authorized up to $1 billion in share repurchases. The 2027 outlook will depend largely on fourth-quarter awards and cancellation trends. * MarketBeat All Access makes it easier to follow Medpace with alerts, analyst ratings, and deeper research - now $149 a year with your rate locked in. Medpace NASDAQ: MEDP reported third-quarter 2026 revenue growth of 8.5% and record net new business awards, while management said the clinical research organization continues to see a strong operating environment marked by healthy request-for-proposal activity, initial award notifications and win rates. Revenue totaled $716 million for the quarter, compared with the prior-year period, while net income rose 23.7% to $137.5 million. Diluted earnings per share increased to $4.84 from $3.86 a year earlier. CEO August Troendle said the company's net new business awards reached an all-time high during the quarter, with trailing 12-month awards growing 23.9%. Third-Quarter results and updated outlook. Chief Financial Officer Kevin Brady said third-quarter EBITDA rose 16% year over year to $172.1 million, producing an EBITDA margin of 24%, up from 22.5% in the prior-year quarter. The margin benefited from lower reimbursable costs, he said. For the first nine months of 2026, Medpace generated revenue of $2.13 billion, up 16.9% from the comparable period in 2025. Year-to-date EBITDA increased 19.5% to $474.9 million, and net income rose 21.1% to $382.7 million. The company raised its full-year 2026 outlook. Medpace now expects: * Revenue of $2.835 billion to $2.855 billion, representing growth of 12% to 12.8% from 2025. * EBITDA of $638 million to $652 million, representing growth of 14.4% to 16.9% from 2025. * Net income of $514 million to $524 million. * Diluted earnings per share of $17.97 to $18.32. The guidance assumes a full-year effective tax rate of 19% to 19.5%, interest income of $22.9 million and 28.6 million diluted weighted-average shares outstanding. Brady said the company's outlook does not assume additional share repurchases. Record awards lift backlog. Net new business awards entering backlog increased 10.6% year over year to $873.4 million in the third quarter. Over the past 12 months, awards totaled $3.02 billion. Ending backlog stood at approximately $3.2 billion as of Sept. 30, up 5.6% from a year earlier. Medpace expects about $1.99 billion of backlog to convert into revenue during the next 12 months. Backlog conversion in the third quarter represented 23.8% of beginning backlog. Troendle said the company's opportunity funnel remains strong. While the number of RFPs has declined somewhat, the total dollar value and quality of pending opportunities have increased. He said client award decisions and project progress are occurring at a relatively normal pace, rather than being delayed. Management said the therapeutic mix has shifted somewhat toward more traditional oncology work, while demand in metabolic programs has been lower recently. However, Troendle said Medpace is again seeing a significant number of pending metabolic opportunities. 2027 view hinges on cancellations and fourth-quarter awards. Medpace plans to provide formal 2027 guidance with its fourth-quarter results in February. Troendle said the company does not see a large disconnect between current analyst consensus estimates and its internal modeling, though management wants more visibility before issuing detailed projections. "Our view on 2027 has moved, and we expect it to continue to move," Troendle said, explaining that fourth-quarter awards and cancellation trends will be important inputs to the company's forecast. The company characterized third-quarter cancellations as toward the higher end of its expected range, though not significant enough to warrant separate disclosure. Troendle said current cancellations are primarily tied to product failures, including products not meeting expectations or encountering safety signals, rather than funding constraints. He added that cancellations can be unpredictable, but said Medpace sees no reason to expect unusually high cancellation levels. If fourth-quarter awards remain strong and cancellations stay within a normal range, management expects its 2027 outlook to improve. Margins, staffing and capital allocation. Brady said direct-service operations performed well in the third quarter, supported by solid utilization and revenue growth that outpaced headcount growth. He cautioned that quarterly margins can fluctuate because of contract timing and accounting effects, but said he does not anticipate a significant margin decline in the fourth quarter. Looking ahead, management expects a headwind in 2027 from a Cincinnati campus expansion that is expected to add about $20 million in operating costs. Troendle said employee turnover remains very low and that wage and benefit cost increases remain within the company's expectations. Medpace generated $216.6 million in operating cash flow during the quarter and ended the period with $705.3 million of cash. Its net days sales outstanding was negative 66 days. The company's top five and top 10 customers accounted for roughly 31% and 39%, respectively, of revenue over the trailing 12 months. Separately, the board on Oct. 20 terminated the prior share-repurchase authorization and approved a new authorization allowing the company to repurchase up to $1 billion of its shares. About Medpace (NASDAQ:MEDP). Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting. Medpace's services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Medpace, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list. While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list. Continue following MarketBeat

Medpace Holdings (NASDAQ:MEDP) beat third quarter estimates, but its shares fell 1.9% in after-hours trading on Wednesday as full-year revenue guidance disappointed investors. The clinical contract research organisation reported adjusted earnings of $4.84 per share, against a consensus of $4.44. Revenue rose 8.5% to $716.0 million from $659.9 million a year earlier, slightly above the $714.47 million estimate. For 2026, Medpace expects revenue of $2.835 billion to $2.855 billion. The midpoint of $2.845 billion is below the analyst consensus of $2.852 billion. Net new business awards rose 10.6% to $873.4 million. Backlog grew 5.6% to $3,167.2 million. The board approved a new $1.0 billion share buyback, effective October 20, 2026 and running through December 31, 2028.

Medpace slumps on solid report - where are the 'holes?' * ALLISON GATLIN * Updated 04:18 PM ET 10/22/2026 There were "no holes to poke" in Medpace Holdings' (MEDP) third-quarter earnings, an analyst said late Wednesday. And, on Thursday, Medpace stock recovered from its post-market malaise. All operating metrics topped expectations, Leerink Partners analyst Michael Cherny said in a report. The company also issued fourth-quarter guidance that came in ahead of analysts' current forecasts. Investors Are Rotating Into Healthcare. Here's Why. Janus Henderson portfolio manager Dan Lyons discusses why he sees opportunities for market outperformance in the healthcare sector as innovations in biotechnology, pharmaceuticals and medical devices proliferate. Investors Are Rotating Into Healthcare. Here's Why. See All Videos "Our best estimate, at least based off a weak/volatile aftermarket, is that implied expectations were higher due to the recent move in both the stock/CRO (contract resource organization) group, leaving a bar that maybe needed to be more overcome," he said. In after-hours trades Wednesday, Medpace stock dipped nearly 2% to 649.70. Ahead of the release, shares climbed 6.4%, closing at 662.48. On Thursday, the stock yo-yoed and closed down 1.3% at 653.96. Medpace shares are forming a cup base with a buy point at 677.90, MarketSurge shows. The stock has a nearly perfect Composite Rating of 97, meaning it trades in the top 3% of all stocks in terms of fundamental and technical measures. All key metrics top forecasts. During the three months ended Sept. 30, Medpace earned $4.84 a share on $716 million in sales. Earnings rose 25% to beat forecasts for $4.44 per share. Sales jumped about 8.5% and topped the Street's call for $714 million, according to FactSet. New orders came in at $873.4 million vs. forecasts for $852.3 million. The company's backlog was $3.17 billion, compared with projections for $3.13 billion. For the year, Medpace guided to earnings of $17.97 to $18.32 per share and $2.835 billion to $2.855 billion in sales. The Street called for $17.61 earnings per share on $2.85 billion in sales. "On the surface this does not feel like a negative surprise of any real magnitude, with the next leg of performance likely driven by where MEDP goes from here," Cherny said. He rates Medpace stock a market perform. IBD newsletters. Get exclusive IBD analysis and actionable news daily. Follow Allison Gatlin on X/Twitter at @AGatlin_IBD. YOU MAY ALSO LIKE: